Therefore, targeted inhibition of PD-L1 can enhance anti-tumor and anti-fibrotic immune responses by reducing M2 macrophages and myeloid-derived suppressor cells in the fibrotic immunosuppressive microenvironment, and increasing the number of effector CD8+ T cells in liver fibrosis induced HCC (175). The gene discussed is CD8A; the disease is Hepatic fibrosis.